Advertisement

Drug delivery to brain tumors: physiological and pharmacokinetic aspects of chemotherapy

  • Ronald G. Blasberg
  • Dennis R. Groothuis
  • Donald C. Wright
  • Peter Molnar

Abstract

It is generally recognized that the benefits from chemotherapy of brain tumors has progressed slowly in comparison to the treatment of many systemic tumors (1). Successful treatment has been limited despite 30 years of drug trials during which various drugs, drug combinations, dosage regi-mens and routes of administration have been stud-ied. Common explanations given for chemothera-peutic failure include tumor insensitivity to a particular drug or combination of drugs, and too narrow a range of drug dosage between tumor cell killing and systemic toxicity. Implicit in phrases such as ‘tumor sensitivity’ and ‘systemic toxicity’ is the exposure of tumor cells and systemic tissues to different concentrations of the administered drug over time. The exposure of various organs and tissues to a chemotherapeutic drug is likely to be different and could contribute to selective toxicity. Similarity, different tumors as well as different re-gions within a single tumor are likely to be exposed to a wide range of drug concentrations (2–4). The question then becomes whether differential tissue-drug exposure contributes in any significant way to tumor response and systemic toxicity or whether the differential sensitivities of tumor and systemic tissues are all due to inherent differences (gene expression) of the tissues themselves.

Keywords

Brain Tumor Plasma Clearance Capillary Permeability Experimental Tumor Human Brain Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Shapiro WR: Brain tumors. In: Pinedo HM (ed) Cancer chemotherapy (annual series, 1979–1983); Elsevier, New York; 1979, pp 452–472; 1980, pp 414-431; 1981, pp 425-441; 1982, pp 397-411, 1983Google Scholar
  2. 2.
    Blasberg RG, Molnar P, Groothuis D, Patlak CS, Owens E and Fenstermacher JD: Concurrent measurements of blood flow and transcapillary transport in ASV-induced experi-mental brain tumors: Implications for brain tumor chemo-therapy. J Pharm Expcr Therap 231(3): 724–735, 1984Google Scholar
  3. 3.
    Horowitz M, Blasberg RG, Molnar P, Strong J, Kornblith P, Pleasants R and Fenstermacher JD: Regional l4C-mis-onidazole distribution in RT-9 brain tumors. Cancer Res 43: 3800–3807, 1983PubMedGoogle Scholar
  4. 4.
    Blasberg RG, Horowitz M, Strong J, Molnar P, Patlak C, Owens E, and Fenstermacher J: Regional measurements of 14C-misonidazole distribution and blood flow in sub-cutaneous RT-9 experimental tumors. Cancer Res 45: 1692–1701, 1985PubMedGoogle Scholar
  5. 5.
    Blasberg RG and Groothuis DR: Chemotherapy of brain tumors: physiological and pharmacokinetic considerations. In Shapiro, W.R. (ed): Seminars in Oncology New York: Grune and Stratton, Inc. 13(1): 70–82, 1986Google Scholar
  6. 6.
    Levin VA, Patlak CS, Landahl HD: Heuristic modeling of drug delivery to malignant brain tumors. J Pharmacokinet Biopharm 8: 257–296, 1980PubMedCrossRefGoogle Scholar
  7. 7.
    Blasberg RG, Kobayashi T, Horowitz M, Rice JM, Groot-huis D, Molnar P, Fenstermacher JD: Regional blood flow in ethylnitrosourea (ENU)-induced brain tumors. Ann Neurol 14: 189–201, 1983PubMedCrossRefGoogle Scholar
  8. 8.
    Vriesendorp FV, Groothuis DR, Vick NA: Murine sar-coma virus induced brain tumors: concurrent measure-ments of blood flow and blood-to-tissue transport. J Neuro-Oncol 2: 301–314, 1984CrossRefGoogle Scholar
  9. 9.
    Blasberg RG, Shapiro WR, Molnar R, Patlak CS and Fenstermachcr JD: Local blood flow in Walker 256 meta-static brain tumors. J Neuro Oncol 2: 195–204, 1984Google Scholar
  10. 10.
    Blasberg RG, Molnar P, Horowitz M, Kornblith P, Pleas-ants R, Fenstermacher JD: Regional blood flow in RT-9 brain tumors. J Neurosurg 58: 863–873, 1983PubMedCrossRefGoogle Scholar
  11. 11.
    Groothuis D, Blasberg RG, Molnar P, Bigner D, Fenster-macher JD: Regional blood flow in avain sarcoma virus (ASV)-induced brain tumors. Neurology (Cleveland) 33: 686–796, 1983Google Scholar
  12. 12.
    Groothuis DR, Fisher JM, Pasternak JF, Blasberg RG, Bigner DD, Vick NA: Regional measurement of blood flow in experimental RG-2 rat gliomas. Cancer Res 43: 3362–3367, 1983PubMedGoogle Scholar
  13. 13.
    Vriesendorp FV, Peagram C, Bigner DD, Groothuis DR: Concurrent measurements of blood flow and transcapillary transport in a xenotransplanted human gliomas in immune suppressed rats. J Natl Cancer Inst (in press)Google Scholar
  14. 14.
    Brooks DJ, Beaney RP, Lammertsma AA, Leenders KL, Horlock PL, Kensett MJ, Marshall J, Thomas DG and Joncs T. Quantitative Measurement of Blood-Brain Barr-ier Permeability Using Rubidium-82 and Positron Emission Tomography. J Cerebral Blood Flow and Metab 4: 535–545, 1984CrossRefGoogle Scholar
  15. 15.
    Rhodes CG, Wise RJS, Gibbs JM, Frackowiak RSJ, Hatazaqa J, Palmer AJ, Thomas DGT, Jones T: In vivo disturbance of the oxidative metabolism of glucose in human cerebral gliomas. Ann Neurol 14: 614–626, 1983PubMedCrossRefGoogle Scholar
  16. 16.
    Bradbury M: The concept of a blood-brain barrier. Wiley-Interscience, New York, 1979Google Scholar
  17. 17.
    Rall DP, Zubrod CG: Mechanisms of drug absorption and excretion: passage of drugs in and out of the central nervous system. Ann Rev Pharmacol 2: 109–128, 1962CrossRefGoogle Scholar
  18. 18.
    Vick NA, Khandekar JD, Bigner DD: Chemotherapy of brain tumors. The ‘blood-brain barrier’ is not a factor. Arch Neurol 34: 523–526, 1977 (Editorial)Google Scholar
  19. 19.
    Blasberg RG: Pharmacokinetics and metastatic brain tu-mor chemotherapy. In: Brain Metastasis. (eds) L Weiss, HA Gilbert, JB Posner, GK Hall, Boston, 1980, pp 146–164Google Scholar
  20. 20.
    Fenstermacher JD, Blasberg RG, Patlak CS: Methods for quantifying the transport of drugs across brain barrier sys-tems. Pharmacol. Ther. 14: 217–248, 1981PubMedCrossRefGoogle Scholar
  21. 21.
    Davson J, Danielli JF: The permeability of natural membranes. Cambridge Univ Press, 1943Google Scholar
  22. 22.
    Fenstermacher JD, Rapoport SI: The blood-brain barrier. In: Handbook of Physiology: The Cardiovascular System IV. (eds) EM Renkin, CC Michel. American Physiological Society, Bethesda, MD pp 969–100, 1984Google Scholar
  23. 23.
    Renkin EM: Transport of potassium-42 from blood to tissue in isolated mammalian skeletal muscle. Am J Physiol 197: 1205–1210, 1959PubMedGoogle Scholar
  24. 24.
    Crone C: Permeability of capillaries in various organs as determined by use of the indicator diffusion method. Acta Physiol Scand 58: 292–305, 1963PubMedCrossRefGoogle Scholar
  25. 25.
    Blasberg RG, Kobayashi T, Horowitz M, Rice JM, Groothuis D, Molnar P, Fenstermacher JD: Regional blood-to-tissue transport in ethylnitrosourea (ENU)-in-duced brain tumors. Ann Neurol 14: 202–215, 1983PubMedCrossRefGoogle Scholar
  26. 26.
    Blasberg RG, Shapiro WR, Molnar P, Patlak CS and Fenstermacher JD: Local blood-to-tissue transport in Walker 256 metastatic brain tumors. J Neuro-Oncol 2: 205–218, 1984Google Scholar
  27. 27.
    Molar P, Blasbcrg RG, Horowitz M, Smith B, Fenster-macher JD: Regional blood-to-tissue transport in RT-9 brain tumors. J Neurosurg 58: 874–884, 1983CrossRefGoogle Scholar
  28. 28.
    Molnar P, Blasberg RG, Groothuis D, Bigner D, Fenster-macher JD: Regional blood-to-tissue transport in avian sarcoma virus (ASV)-induced brain tumors. Neurology (Cleveland) 33: 702–711, 1983Google Scholar
  29. 29.
    Groothuis DR, Fisher JM, Pasternak JF, Blasberg RG, Bigner DD, Vick NA: Regional measurements of blood-to-tissue transport in experimental RG-2 rat gliomas. Can-cer Res 43: 3368–3373, 1983Google Scholar
  30. 30.
    Groothuis DR, Vriesendorp FV, Michael M, Blasberg RG, Patlak CS: Quantitative measurement of brain tumor capil-lary permeability by CT: application in canine gliomas and implications for use in patients. Neurology 34(Suppl. 1), 185–186, 1984Google Scholar
  31. 31.
    Hawkins RA, Phelps ME, Huang SC, Wapenski JA, Grimm PD, Parker RG, Juillard G and Greenberg P: A Kinetic Evaluation of Blood-Brain Barrier Permeability in Human Brain Tumors with (68Ga)EDTA and Positron Computed Tomography. J Cerebral Blood Flow and Metab 4: 507–515. 1984CrossRefGoogle Scholar
  32. 32.
    Breithaupt H, Kuenzlen E: Pharmacokinetics of meth-otrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate. Cancer Treat Rep 66: 1733–1741, 1982PubMedGoogle Scholar
  33. 33.
    Levin VA, Hoffman W, Weinkam RJ: Pharmacokinetics of BCNU in man: a preliminary study of 20 patients. Cancer Treat Rep 62: 1305–1312, 1978PubMedGoogle Scholar
  34. 34.
    Sakurada O, Kennedy C, Jehle J et al: Measurement of local cerebral blood flow with Iodo(l4C)-antipyrine. Am J Physiol 234(1): H59–H66, 1978PubMedGoogle Scholar
  35. 35.
    Blasberg RG, Groothuis D and Molnar P: Application of quantiative autoradiographic measurements in experimen-tal brain tumor models. Semin Neurol 1: 203–223, 1981CrossRefGoogle Scholar
  36. 36.
    Blasberg RG, Fenstermacher JD and Patlak CS: The trans-port of alpha-aminoisobutyric acid across brain capillary and cellular membranes. J Cereb Blood Flow Metab 3: 8–32, 1983PubMedCrossRefGoogle Scholar

Copyright information

© Martinas Nijhoff Publishers, Boston 1986

Authors and Affiliations

  • Ronald G. Blasberg
    • 1
  • Dennis R. Groothuis
    • 2
  • Donald C. Wright
    • 3
  • Peter Molnar
    • 4
  1. 1.Nuclear Medicine DepartmentNational Institutes of HealthBethesdaUSA
  2. 2.Department of NeurologyNorthwestern University, Evanston HospitalEvanstonUSA
  3. 3.Clinical Neurosurgery SectionSNB, NINCDS, National Institutes of HealthBethesdaUSA
  4. 4.Department of PathologyUniversity Medical School of DebrecenDebrecenHungary

Personalised recommendations